|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date09 Apr 1985 |
Phase II Randomized Trial of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC).
The goal of this study is to determine whether the addition of Androgen Deprivation Therapy (ADT) utilizing the study drug ELIGARD® to Recurrence- Directed Therapy (RDT) improves progression-free survival (PFS) compared to RDT alone in patients with early radio-recurrent oligo-metastatic castrate / hormone sensitive prostate cancer (romCSPC). Participants will be assessed at standard of care clinic visits every 3 months. The follow-up period is 36 months.
100 Clinical Results associated with Tolmar Pharmaceuticals Canada, Inc
0 Patents (Medical) associated with Tolmar Pharmaceuticals Canada, Inc
100 Deals associated with Tolmar Pharmaceuticals Canada, Inc
100 Translational Medicine associated with Tolmar Pharmaceuticals Canada, Inc